Minerva Neurosciences, Inc. (NERV) News
Track canonical SquawkNews coverage tagged to NERV, Minerva Neurosciences, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
NERV: Roluperidone's pivotal phase III trial is on track, with results expected next year and strong investor support
The conference highlighted progress in developing roluperidone for negative symptoms of schizophrenia, with a confirmatory phase III trial underway and results expected in the second half of next year. Strong IP protecti
EQUITY | Sep 09, 2026, 08:15 PM UTC
L
NERV says roluperidone phase III trial is on track; results due next year
NERV is advancing roluperidone for negative symptoms of schizophrenia with a confirmatory phase III trial underway. Results are expected in the second half of next year.
EARNINGS | Sep 09, 2026, 07:43 PM UTC
L
Minerva Neurosciences to participate in two upcoming investor conferences
Minerva Neurosciences plans to participate in two upcoming investor conferences.
EQUITY | Aug 28, 2026, 12:07 PM UTC
L
NERV - Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
NERV - Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
EQUITY | Aug 28, 2026, 12:00 PM UTC
L
Analysts raise views on CAPR, DLR, FOXA, LTC, NERV, NYAX
Analysts upgrade CAPR to Overweight at Cantor, DLR to Buy at HSBC, FOXA to Overweight at JPM, LTC to Outperform at RBC, NERV to Buy at Jefferies, and NYAX to Outperform at Keefe.
EQUITY | Aug 14, 2026, 10:28 AM UTC